Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Related Questions
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
What would be the recommended sequencing of adjuvant chemotherapy, osimertinib, and postoperative radiation for a patient with NSCLC who was upstaged to stage III following resection with negative margins?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
What second line therapy do you use for metastatic thymoma that recurs following CAP?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
How would you approach first-line treatment in metastatic NSCLC for a patient with ALK-EML4 V3a/b variant and MSI-high status?